Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS: Response to the editor.

Vukusic S, Durand-Dubief F, Marignier R.

Mult Scler. 2020 Feb 5:1352458520904549. doi: 10.1177/1352458520904549. [Epub ahead of print] No abstract available.

PMID:
32022648
2.

New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions.

Brisset JC, Kremer S, Hannoun S, Bonneville F, Durand-Dubief F, Tourdias T, Barillot C, Guttmann C, Vukusic S, Dousset V, Cotton F; Collaborators.

J Neuroradiol. 2020 Jan 31. pii: S0150-9861(20)30095-X. doi: 10.1016/j.neurad.2020.01.083. [Epub ahead of print] Review.

PMID:
32014494
3.

Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: A multicenter cross-sectional study.

Cobo-Calvo Á, d'Indy H, Ruiz A, Collongues N, Kremer L, Durand-Dubief F, Rollot F, Casey R, Vukusic S, De Seze J, Marignier R.

Neurol Neuroimmunol Neuroinflamm. 2019 Dec 13;7(2). pii: e649. doi: 10.1212/NXI.0000000000000649. Print 2020 Mar.

4.

The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab.

Nicolas P, Ruiz A, Cobo-Calvo A, Fiard G, Giraudon P, Vukusic S, Marignier R.

Front Immunol. 2019 Nov 19;10:2686. doi: 10.3389/fimmu.2019.02686. eCollection 2019.

5.

MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests.

Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Mayran P, Bieuvelet S, Vallée M, Bertillot F, Klaeylé L, Argoud AL, Zinaï S, Tourbah A.

Eur J Neurol. 2020 Mar;27(3):429-436. doi: 10.1111/ene.14091. Epub 2019 Oct 19.

PMID:
31538396
6.

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA; OFSEP Investigators.

JAMA Neurol. 2019 Sep 3. doi: 10.1001/jamaneurol.2019.2670. [Epub ahead of print]

PMID:
31479149
7.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

8.

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease.

Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Deschamps R, Solà-Valls N, Llufriu S, De Seze J, Blanco Y, Vukusic S, Saiz A, Marignier R.

J Neuroinflammation. 2019 Jul 2;16(1):134. doi: 10.1186/s12974-019-1525-1.

9.

Gabapentin and Memantine for Treatment of Acquired Pendular Nystagmus: Effects on Visual Outcomes.

Nerrant E, Abouaf L, Pollet-Villard F, Vie AL, Vukusic S, Berthiller J, Colombet B, Vighetto A, Tilikete C.

J Neuroophthalmol. 2019 Jun 3. doi: 10.1097/WNO.0000000000000807. [Epub ahead of print]

PMID:
31169568
10.

Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society.

Lebrun C, Vukusic S; French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SFSEP).

Mult Scler Relat Disord. 2019 Jun;31:173-188. doi: 10.1016/j.msard.2019.04.004. Epub 2019 Apr 10. Review.

PMID:
31159998
11.

Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.

Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, Collongues N, Deschamps R, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Zephir H, Bereau M, Brochet B, Carra-Dallière C, Derache N, Gagou-Scherer C, Henry C, Kerschen P, Mathey G, Maubeuge N, Maurousset A, Montcuquet A, Moreau T, Prat C, Taithe F, Thouvenot E, Tourbah A, Rollot F, Vukusic S, Marignier R.

Mult Scler. 2019 May 31:1352458519849511. doi: 10.1177/1352458519849511. [Epub ahead of print]

PMID:
31148523
12.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
13.

Spontaneous multiple cervical artery dissections after alemtuzumab.

Durand-Dubief F, Marignier R, Berthezene Y, Cottin J, Nighoghossian N, Vukusic S.

Mult Scler. 2019 May 9:1352458519828663. doi: 10.1177/1352458519828663. [Epub ahead of print]

PMID:
31070502
14.

Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.

Lebrun C, Vukusic S; French Group for Recommendations in Multiple Sclerosis (France4MS), the Société francophone de la sclérose en plaques (SFSEP).

Rev Neurol (Paris). 2019 Jun;175(6):341-357. doi: 10.1016/j.neurol.2019.04.001. Epub 2019 Apr 27.

PMID:
31036391
15.

Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.

Ayrignac X, Rigau V, Lhermitte B, Vincent T, de Champfleur NM, Carra-Dalliere C, Charif M, Collongues N, de Seze J, Hebbadj S, Ahle G, Oesterlé H, Cotton F, Durand-Dubief F, Marignier R, Vukusic S, Taithe F, Cohen M, Guennoc AM, Kerbrat A, Edan G, Carsin-Nicol B, Allou T, Sablot D, Thouvenot E, Ruet A, Magy L, Boncoeur-Martel MP, Labauge P, Kremer S.

J Neurol. 2019 Jul;266(7):1743-1755. doi: 10.1007/s00415-019-09328-7. Epub 2019 Apr 23.

PMID:
31016376
16.

Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease.

Ameli R, R G Guttmann C, Prieto JC, Rollot F, Palotai M, Vukusic S, Marignier R, Cotton F; Group Members for OFSEP Imaging Working, COPIL of OFSEP, the NOMADMUS study group.

J Neuroradiol. 2019 Apr 11. pii: S0150-9861(18)30337-7. doi: 10.1016/j.neurad.2019.03.015. [Epub ahead of print]

PMID:
30981824
17.

Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.

Vukusic S, Coyle PK, Jurgensen S, Truffinet P, Benamor M, Afsar S, Purvis A, Poole EM, Chambers C.

Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055. [Epub ahead of print]

PMID:
30968734
18.

Cranial nerve involvement in patients with MOG antibody-associated disease.

Cobo-Calvo A, Ayrignac X, Kerschen P, Horellou P, Cotton F, Labauge P, Vukusic S, Deiva K, Serguera C, Marignier R.

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 1;6(2):e543. doi: 10.1212/NXI.0000000000000543. eCollection 2019 Mar.

19.

Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults.

Cobo-Calvo A, Vukusic S, Marignier R.

Curr Opin Neurol. 2019 Jun;32(3):459-466. doi: 10.1097/WCO.0000000000000681. Review.

PMID:
30762607
20.

Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Apr;266(4):816. doi: 10.1007/s00415-019-09215-1.

PMID:
30759286
21.

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C.

Mult Scler Relat Disord. 2019 Apr;29:7-14. doi: 10.1016/j.msard.2019.01.019. Epub 2019 Jan 6.

PMID:
30654246
22.

Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Apr;266(4):806-815. doi: 10.1007/s00415-018-9160-9. Epub 2019 Jan 3. Erratum in: J Neurol. 2019 Feb 7;:.

PMID:
30607536
23.

Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases.

Codjia P, Ayrignac X, Carra-Dalliere C, Cohen M, Charif M, Lippi A, Collongues N, Corti L, De Seze J, Lebrun C, Vukusic S, Durand-Dubief F, Labauge P; SFSEP and OFSEP.

Mult Scler Relat Disord. 2019 Feb;28:109-116. doi: 10.1016/j.msard.2018.12.022. Epub 2018 Dec 18.

PMID:
30592992
24.

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M.

Mult Scler. 2020 Jan;26(1):118-122. doi: 10.1177/1352458518815602. Epub 2018 Dec 13.

PMID:
30541380
25.

Author Correction: Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 22;4(1):49. doi: 10.1038/s41572-018-0050-3.

PMID:
30467372
26.

Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Review. Erratum in: Nat Rev Dis Primers. 2018 Nov 22;4(1):49.

PMID:
30410033
27.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
28.

Where there is inflammation, treatment may reduce disability progression - No.

Edan G, Vukusic S.

Mult Scler. 2018 Oct 8:1352458518795417. doi: 10.1177/1352458518795417. [Epub ahead of print] No abstract available.

PMID:
30295565
29.

Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure.

Commowick O, Istace A, Kain M, Laurent B, Leray F, Simon M, Pop SC, Girard P, Améli R, Ferré JC, Kerbrat A, Tourdias T, Cervenansky F, Glatard T, Beaumont J, Doyle S, Forbes F, Knight J, Khademi A, Mahbod A, Wang C, McKinley R, Wagner F, Muschelli J, Sweeney E, Roura E, Lladó X, Santos MM, Santos WP, Silva-Filho AG, Tomas-Fernandez X, Urien H, Bloch I, Valverde S, Cabezas M, Vera-Olmos FJ, Malpica N, Guttmann C, Vukusic S, Edan G, Dojat M, Styner M, Warfield SK, Cotton F, Barillot C.

Sci Rep. 2018 Sep 12;8(1):13650. doi: 10.1038/s41598-018-31911-7.

30.

"Myelitis migrans": A rare cause of treatable myelitis.

Jaulent P, Pegat A, Grosset-Janin C, Durand-Dubief F, Vukusic S, Marignier R.

Rev Neurol (Paris). 2018 Dec;174(10):745-747. doi: 10.1016/j.neurol.2017.12.005. Epub 2018 Aug 22. No abstract available.

PMID:
30143322
31.

Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus?

Jaulent P, Hannoun S, Kocevar G, Rollot F, Durand-Dubief F, Vukusic S, Brisset JC, Sappey-Marinier D, Cotton F.

Eur J Radiol. 2018 Aug;105:204-208. doi: 10.1016/j.ejrad.2018.06.011. Epub 2018 Jun 19.

PMID:
30017281
32.

Unusual neurologic presentation of aseptic abscesses syndrome.

Nicolas P, Guerrier O, Benoit A, Durand-Dubief F, Raverot G, Debarbieux S, Delteil C, Vasiljevic A, Jouanneau E, Cotton F, Marignier R, Vukusic S.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 5;5(4):e469. doi: 10.1212/NXI.0000000000000469. eCollection 2018 Jul. No abstract available.

33.

Efficacy of rituximab in refractory RRMS.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B.

Mult Scler. 2019 May;25(6):828-836. doi: 10.1177/1352458518772748. Epub 2018 May 3.

PMID:
29722639
34.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
35.

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP.

Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30. Review.

PMID:
29606320
36.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
37.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
38.

Weekly follow up of acute lesions in three early multiple sclerosis patients using MR spectroscopy and diffusion.

Kocevar G, Stamile C, Hannoun S, Roch JA, Durand-Dubief F, Vukusic S, Cotton F, Sappey-Marinier D.

J Neuroradiol. 2018 Mar;45(2):108-113. doi: 10.1016/j.neurad.2017.06.010. Epub 2017 Oct 13.

PMID:
29032126
39.

Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey.

Jardel S, Fabien N, Hot A, Vukusic S, Tebib J, Cottin V, Sève P, Laville M, Belot A, Durieu I, Garnier L, Coutant F, Reynaud Q, Lega JC.

PLoS One. 2017 Sep 20;12(9):e0185104. doi: 10.1371/journal.pone.0185104. eCollection 2017.

40.

MOG antibody-related disorders: common features and uncommon presentations.

Cobo-Calvo Á, Ruiz A, D'Indy H, Poulat AL, Carneiro M, Philippe N, Durand-Dubief F, Deiva K, Vukusic S, Desportes V, Marignier R.

J Neurol. 2017 Sep;264(9):1945-1955. doi: 10.1007/s00415-017-8583-z. Epub 2017 Aug 2.

PMID:
28770374
41.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
42.

Electrophysiological Correlates of Subliminal Perception of Facial Expressions in Individuals with Autistic Traits: A Backward Masking Study.

Vukusic S, Ciorciari J, Crewther DP.

Front Hum Neurosci. 2017 May 23;11:256. doi: 10.3389/fnhum.2017.00256. eCollection 2017.

43.

Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey.

Dumortier J, Cottin J, Lavie C, Guillaud O, Hervieu V, Chambon-Augoyard C, Scoazec JY, Vukusic S, Vial T.

Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):497-501. doi: 10.1016/j.clinre.2017.03.008. Epub 2017 Apr 21.

PMID:
28438569
44.

Multiple sclerosis broke my heart.

Androdias G, Bernard E, Biotti D, Collongues N, Durand-Dubief F, Pique J, Sanchez I, Delmas C, Ninet J, Marignier R, Vukusic S.

Ann Neurol. 2017 May;81(5):754-758. doi: 10.1002/ana.24935. Epub 2017 May 9.

PMID:
28437859
45.

Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients.

Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, Maucort-Boulch D, Marquet A, Pérard L, Bouillet L, Deroux A, Abad S, Bielefeld P, Bouvry D, André M, Noel N, Bienvenu B, Proux A, Vukusic S, Bodaghi B, Sarrot-Reynauld F, Iwaz J, Amoura Z, Broussolle C, Cacoub P, Saadoun D, Valeyre D, Sève P; Groupe Sarcoïdose Francophone.

Semin Arthritis Rheum. 2017 Oct;47(2):288-294. doi: 10.1016/j.semarthrit.2017.03.005. Epub 2017 Mar 8.

PMID:
28392046
46.

Primary and secondary progressive MS have a similar age at onset of progression - YES.

Vukusic S.

Mult Scler. 2017 Apr;23(5):638-639. doi: 10.1177/1352458517690273. No abstract available.

PMID:
28357926
47.

Neuromyelitis optica and neuromyelitis optica spectrum disorders.

Marignier R, Cobo Calvo A, Vukusic S.

Curr Opin Neurol. 2017 Jun;30(3):208-215. doi: 10.1097/WCO.0000000000000455. Review.

PMID:
28306572
48.

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, Edan G, Leray E, Moreau T, Vukusic S, Hédelin G, Guillemin F.

PLoS One. 2016 Dec 9;11(12):e0167556. doi: 10.1371/journal.pone.0167556. eCollection 2016.

49.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
50.

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.

Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, Uhry Z, Van Ganse E, Castot A, Clanet M, Lubetzki C, Confavreux C; TYSEDMUS and OFSEP Group.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297. eCollection 2016 Dec.

Supplemental Content

Loading ...
Support Center